Efficacy of antineoplastons A10 and AS2-1.
Burzynski
S R
SR
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D044482:Benzeneacetamides; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005910:Glioma / Q000097:blood / Q000188:drug therapy* / Q000556:secondary; D005973:Glutamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D009316:National Institutes of Health (U.S.); D010648:Phenylacetates / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D010881:Piperidones / Q000008:administration & dosage* / Q000009:adverse effects; D017211:Treatment Failure; D014481:United States
D000970:Antineoplastic Agents; D044482:Benzeneacetamides; D004338:Drug Combinations; D010648:Phenylacetates; D010881:Piperidones; D005973:Glutamine; C092038:antineoplaston AS 2-1; C052091:antineoplaston A10; C003089:phenylacetylglutamine; C025136:phenylacetic acid